

[EBMT](#)

[Annual report](#)

[2023](#)



[Science Education Patient Care & Advocacy](#)

[Our Society](#) [Our Mission, Vision & Values](#) [EBMT Membership 2023](#) [Organisational Structure 2023](#) [Financial Highlights 2023](#) [EBMT Partners](#)

Breadcrumb

1. [Home](#)

Entity Print




Raffaella Greco
ADWP Chair
Italy

Major achievements

Autoimmune diseases (ADs) are a heterogeneous group of diseases, characterized by loss of immune tolerance, high chronicity, with substantial morbidity and mortality. Over the last 3 decades, hematopoietic stem cell transplantation (HCT) has been increasingly used to treat patients affected by severe and refractory ADs, and is recently facing a unique developmental phase across EBMT centers.

Autologous HCT has become a standard-of-care part of treatment algorithms in multiple sclerosis and systemic sclerosis. Recently, innovative cellular therapies (i.e. CAR-T cells, mesenchymal cells, Tregs-based therapies) have been successfully adopted in ADs.

The EBMT Autoimmune Diseases Working Party (ADWP) has been central to development of these approaches. The ADWP is dedicated to promoting clinical activities, teaching and translational research on HCT together with innovative cellular therapies as AD treatment, to re-induce self-tolerance by resetting the immune system. The ADs section of the EBMT Registry is the largest database of its kind worldwide, with over 4,300 HCT registrations.



A multidisciplinary approach is key in this field, and ADWP is continuing to expand the evidence-base and support best-practice with studies and guidelines, including significant collaborative outputs with EBMT Working-Parties, JACIE, Trainee-Committee, PAC and Nurses-Group.

Education is central in ADWP activities, including a successful joint Midterm Educational Meeting on New indications in Immune Dysregulatory, Autoinflammatory and Autoimmune Diseases, and Harmonization Workshop on innovative cellular

therapies for ADs. Moreover, a section specifically designed for ADs was developed within the EBMT e-learning platform with contributions from key experts in the field.



ADWP Team during the 49th Annual Meeting of the EBMT in Paris

Principal research studies

[Comparison of Cyclophosphamide/ATG vs BEAM/ATG conditioning regimens in autologous HSCT for Multiple Sclerosis](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Auto immune disorders](#)

[Group](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)

[Type of treatment](#)

[Autologous](#)

[Principal investigator](#)

[Riccardo Saccardi](#)

[LATE COMPLICATIONS AFTER AUTOLOGOUS HSCT FOR AUTOIMMUNE DISEASES: a retrospective survey from the Autoimmune Diseases Working Party \(ADWP\) and Transplant Complications Working Party \(TCWP\) of the European Society for Blood and Marrow Transplantation \(EBMT\)](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Group](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)

[Transplant Complications Working Party \(TCWP\)](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

Type of treatment

Autologous

Principal investigator

Kirill Kirgizov

Post AHSCT (Autologous Hematopoietic Stem Cell Transplantation) management for patients with systemic sclerosis: a prospective, non-interventional approach across Europe (NISSC-2)

Study type

Non-interventional Prospective Studies

Diseases

-

Group

Autoimmune Diseases Working Party (ADWP)

Type of treatment

Autologous

Principal investigator

Pr Dominique Farge

Observational Study in Multiple Sclerosis patients treated with autologous hematopoietic stem cell Transplantation (OMST)

Study type

Non-interventional Prospective Studies

Diseases

Auto immune disorders

Group

Autoimmune Diseases Working Party (ADWP)

Type of treatment

Autologous

Principal investigator

Riccardo Saccardi

Incidence and outcome of CMV and EBV reactivations after autologous HSCT for autoimmune diseases: a retrospective survey from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Study type

Retrospective Studies

Diseases

Auto immune disorders

Group

[Autoimmune Diseases Working Party \(ADWP\)](#)

[Type of treatment](#)

-

[Principal investigator](#)

[Tobias Alexander](#)

Key publications

[2023](#)

[Autoimmune manifestations in VEXAS: Opportunities for integration and pitfalls to interpretation](#)

[Group](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)

[1st listed author](#)

[Alessandro Bruno](#)

[Journal](#)

[J Allergy Clin Immunol.](#)

[2023](#)

[Outcome of SARS-CoV2 infection in hematopoietic stem cell transplant recipients for autoimmune diseases](#)

[Group](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)

[Infectious Diseases Working Party \(IDWP\)](#)

[1st listed author](#)

[Raffaella Greco](#)

[Journal](#)

[J Autoimmun.](#)

[2023](#)

[Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update](#)

[Group](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)


[1st listed author](#)

[Alice Mariottini](#)

[Journal](#)

[Bioengineering \(Basel\).](#)

Impact factor (Autoimmune Diseases)



2021 2022 2023

Oral presentations

19 22 **16**

Poster presentations

1 1 **4**

International educational events

2 3 **3**



[Event](#)

49th Annual Meeting of the EBMT



Event

Midterm Meeting on New indications in Immune Dysregulatory, Autoinflammatory and Autoimmune Diseases

Jun 22, 2023 - Jun 24, 2023 / Brescia, Italy

Discover more

Webinars and e-courses

HSCT in Autoimmune Diseases E-Course

Panel Discussion: Autologous HSCT in Multiple Sclerosis

VISIT THE ADWP WEBPAGE